MAP7D3

Summary

MAP7D3 (MAP7 domain containing 3, HGNC:25742) is a protein-coding gene on chromosome Xq26.3, encoding MAP7 domain-containing protein 3 (Q8IWC1). Promotes the assembly and stability of microtubules.

The protein encoded by this gene belongs to the MAP7 (microtubule-associated protein 7) family. Alternatively spliced transcript variants encoding different isoforms have been found.

Source: NCBI Gene 79649 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC)
• Clinical variants (ClinVar): 244 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_024597

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25742
Approved symbol	MAP7D3
Name	MAP7 domain containing 3
Location	Xq26.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ12649
Ensembl gene	ENSG00000129680
Ensembl biotype	protein_coding
OMIM	300930
Entrez	79649

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 11 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000316077, ENST00000370660, ENST00000370661, ENST00000370663, ENST00000471510, ENST00000477124, ENST00000489788, ENST00000495432, ENST00000937863, ENST00000937864, ENST00000937865, ENST00000937866, ENST00000937867, ENST00000945657, ENST00000945658

RefSeq mRNA: 3 — MANE Select: NM_024597 NM_001173516, NM_001173517, NM_024597

CCDS: CCDS44004, CCDS55508, CCDS55509

Canonical transcript exons

ENST00000316077 — 19 exons

Exon	Start	End
ENSE00000676989	136230839	136230966
ENSE00000676990	136231544	136232220
ENSE00000676991	136236244	136236339
ENSE00000676992	136240382	136240486
ENSE00001325984	136241160	136241277
ENSE00001641055	136246243	136246341
ENSE00001657381	136246065	136246148
ENSE00001675663	136244632	136244795
ENSE00001736798	136220765	136220963
ENSE00001923781	136216814	136218493
ENSE00001934656	136251289	136251400
ENSE00002231103	136228623	136228758
ENSE00003511655	136225909	136226013
ENSE00003598654	136227284	136227431
ENSE00003605177	136230385	136230593
ENSE00003618531	136219593	136219671
ENSE00003620963	136224827	136224880
ENSE00003623722	136219398	136219495
ENSE00003638306	136222393	136222486

Expression profiles

Bgee: expression breadth ubiquitous, 203 present calls, max score 98.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.0546 / max 519.4903, expressed in 1765 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200638	19.1738	1763
200639	0.4999	225
200637	0.3299	148
200645	0.0212	7
200642	0.0123	2
200643	0.0102	5
200641	0.0036	1
200644	0.0024	1
200640	0.0012	1

Top tissues by expression

266 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	98.12	gold quality
tendon	UBERON:0000043	94.27	gold quality
popliteal artery	UBERON:0002250	92.38	gold quality
tibial artery	UBERON:0007610	92.38	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	91.62	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.16	gold quality
aorta	UBERON:0000947	90.20	gold quality
right ovary	UBERON:0002118	89.77	gold quality
sural nerve	UBERON:0015488	89.52	gold quality
right coronary artery	UBERON:0001625	89.38	gold quality
descending thoracic aorta	UBERON:0002345	88.43	gold quality
left ovary	UBERON:0002119	88.22	gold quality
left coronary artery	UBERON:0001626	88.04	gold quality
tendon of biceps brachii	UBERON:0008188	87.77	gold quality
thoracic aorta	UBERON:0001515	87.74	gold quality
ascending aorta	UBERON:0001496	87.65	gold quality
mucosa of stomach	UBERON:0001199	87.55	gold quality
left testis	UBERON:0004533	87.47	gold quality
subcutaneous adipose tissue	UBERON:0002190	87.21	gold quality
omental fat pad	UBERON:0010414	87.04	gold quality
peritoneum	UBERON:0002358	86.96	gold quality
right testis	UBERON:0004534	86.91	gold quality
coronary artery	UBERON:0001621	86.74	gold quality
left uterine tube	UBERON:0001303	86.61	gold quality
testis	UBERON:0000473	86.32	gold quality
adipose tissue of abdominal region	UBERON:0007808	86.29	gold quality
lower esophagus muscularis layer	UBERON:0035833	86.16	gold quality
lower esophagus	UBERON:0013473	86.08	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	86.02	gold quality
colonic epithelium	UBERON:0000397	85.41	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.81

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

77 targeting MAP7D3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4782-3P	99.88	73.31	735
HSA-MIR-6766-3P	99.88	73.38	732
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-8076	99.78	68.52	1170
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-26A-1-3P	99.64	66.81	788
HSA-MIR-26A-2-3P	99.64	66.82	786

Literature-anchored findings (GeneRIF, showing 6)

• Mdp3 is a novel microtubule-binding protein that regulates microtubule assembly and stability. (PMID:22142902)
• the amino-terminal region mediated the interaction of Mdp3 with histone deacetylase 6 (HDAC6), in addition to its association with tubulin and microtubules. (PMID:24614595)
• Results have identified a new microtubule binding region in MAP7D3, formed by the conserved MAP7 domain and the C-terminal tail, which can bind to microtubules and promote their assembly and stability. (PMID:24927501)
• A critical role for Mdp3 in the growth and metastasis of breast cancer. (PMID:25161703)
• Mdp3 (also known as MAP7D3) forms a complex with DDA3 (also known as PSRC1) and controls spindle dynamics at the minus end of Microtubuless by inhibiting DDA3-mediated Kif2a recruitment to the spindle. (PMID:27284004)
• MAP7 proteins are microtubule-tethered kinesin-1 activators, with which the motor transiently interacts as it moves along microtubules. (PMID:30770434)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	map7d3	ENSDARG00000060771
mus_musculus	Map7d3	ENSMUSG00000067878
rattus_norvegicus	Map7d3	ENSRNOG00000027831
drosophila_melanogaster	ens	FBGN0264693

Paralogs (3): MAP7D1 (ENSG00000116871), MAP7 (ENSG00000135525), MAP7D2 (ENSG00000184368)

Protein

Protein identifiers

MAP7 domain-containing protein 3 — Q8IWC1 (reviewed: Q8IWC1)

All UniProt accessions (2): Q8IWC1, A0A0A0MRP0

UniProt curated annotations — full annotation on UniProt →

Function. Promotes the assembly and stability of microtubules.

Subunit / interactions. Interacts (via N-terminus coiled coil domains) with tubulin and microtubules.

Subcellular location. Cytoplasm. Cytoskeleton. Spindle.

Induction. Expression is cell cycle dependent with the highest levels during G1, S, and M phases, and low level in G2 phase.

Similarity. Belongs to the MAP7 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8IWC1-1	1	yes
Q8IWC1-2	2
Q8IWC1-3	3
Q8IWC1-4	4

RefSeq proteins (3): NP_001166987, NP_001166988, NP_078873* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008604	MAP7_fam	Family
IPR051483	MAP7_domain-containing	Family

Pfam: PF05672

UniProt features (45 total): compositionally biased region 13, modified residue 11, region of interest 7, sequence conflict 4, coiled-coil region 3, splice variant 3, sequence variant 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IWC1-F1	56.22	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (11): 1, 185, 322, 441, 457, 461, 490, 524, 770, 817, 832

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 90 (showing top): MODULE_511, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN, GOBP_MICROTUBULE_POLYMERIZATION, GOCC_SPINDLE, GOMF_CYTOSKELETAL_PROTEIN_BINDING, FIGUEROA_AML_METHYLATION_CLUSTER_1_UP, FIGUEROA_AML_METHYLATION_CLUSTER_2_UP, FIGUEROA_AML_METHYLATION_CLUSTER_3_UP, FIGUEROA_AML_METHYLATION_CLUSTER_4_UP, FIGUEROA_AML_METHYLATION_CLUSTER_6_UP, FIGUEROA_AML_METHYLATION_CLUSTER_7_UP, chrXq26, MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP, GOBP_MICROTUBULE_CYTOSKELETON_ORGANIZATION

GO Biological Process (2): microtubule cytoskeleton organization (GO:0000226), microtubule polymerization (GO:0046785)

GO Molecular Function (2): microtubule binding (GO:0008017), tubulin binding (GO:0015631)

GO Cellular Component (5): spindle (GO:0005819), microtubule cytoskeleton (GO:0015630), membrane (GO:0016020), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membraneless organelle	2
cellular anatomical structure	2
cytoskeleton organization	1
microtubule-based process	1
microtubule nucleation	1
microtubule polymerization or depolymerization	1
protein polymerization	1
supramolecular fiber organization	1
tubulin binding	1
cytoskeletal protein binding	1
microtubule cytoskeleton	1
cytoskeleton	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1126 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAP7D3	FAM47B	Q8NA70	524
MAP7D3	SATL1	Q86VE3	517
MAP7D3	NOC3L	Q8WTT2	476
MAP7D3	ARSF	P54793	450
MAP7D3	MARCHF9	Q86YJ5	424
MAP7D3	MAPRE3	Q9UPY8	419
MAP7D3	C6orf118	Q5T5N4	418
MAP7D3	MAP9	Q49MG5	407
MAP7D3	DHX36	Q9H2U1	405
MAP7D3	RAB3C	Q96E17	397
MAP7D3	GPR149	Q86SP6	396
MAP7D3	NECAP2	Q9NVZ3	393
MAP7D3	KIF5C	O60282	392
MAP7D3	TRIM46	Q7Z4K8	391
MAP7D3	INTS6L	Q5JSJ4	375

IntAct

99 interactions, top by confidence:

A	B	Type	Score
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
CHCHD4	SSNA1	psi-mi:“MI:0914”(association)	0.640
YWHAG	BLTP3B	psi-mi:“MI:0914”(association)	0.640
YWHAG	BLTP3B	psi-mi:“MI:2364”(proximity)	0.640
YWHAB	BLTP3B	psi-mi:“MI:2364”(proximity)	0.610
YWHAH	BLTP3B	psi-mi:“MI:0914”(association)	0.570
YWHAH	BLTP3B	psi-mi:“MI:2364”(proximity)	0.570
CEP104	CCDC66	psi-mi:“MI:2364”(proximity)	0.540
TUBB3	POTEF	psi-mi:“MI:0914”(association)	0.530
PNMA2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
CBY1	CFAP410	psi-mi:“MI:0914”(association)	0.510
KIAA0753	OFD1	psi-mi:“MI:2364”(proximity)	0.480
GSK3B	SEC16A	psi-mi:“MI:2364”(proximity)	0.420
MAP7D3	RPS10	psi-mi:“MI:0915”(physical association)	0.400
MAP7D3	HNRNPM	psi-mi:“MI:0915”(physical association)	0.400
Calml3	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
RBPJ	SAMD1	psi-mi:“MI:0914”(association)	0.350
RBPJ	RPA2	psi-mi:“MI:0914”(association)	0.350
TUBA1A	CAPZB	psi-mi:“MI:0914”(association)	0.350
TUBA1A	KIF2A	psi-mi:“MI:0914”(association)	0.350
RIPK4	VWA8	psi-mi:“MI:0914”(association)	0.350
PB2	PIK3R2	psi-mi:“MI:0914”(association)	0.350
PB1	ESYT2	psi-mi:“MI:0914”(association)	0.350
CHCHD4	HAX1	psi-mi:“MI:0914”(association)	0.350
YWHAQ	MCRIP1	psi-mi:“MI:0914”(association)	0.350
CBX5	ZNF568	psi-mi:“MI:0914”(association)	0.350
CALM2	MYO1C	psi-mi:“MI:0914”(association)	0.350
CALM3	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
YWHAG	FOXO6	psi-mi:“MI:0914”(association)	0.350

BioGRID (171): MAP7D3 (Affinity Capture-MS), MAP7D3 (Affinity Capture-MS), MAP7D3 (Affinity Capture-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS), MAP7D3 (Proximity Label-MS)

ESM2 similar proteins: A0A2K1J5A5, A0A2K1JJ00, A1Z7A8, A2AEY4, A2AWL7, A6NCI8, B4IH30, B4P8I0, E9PVX6, E9Q309, O14513, O43303, O60284, O94243, P40167, P46013, P51954, Q10668, Q11114, Q3ZBP0, Q498L0, Q4QY64, Q4V7J0, Q5BI31, Q5SW79, Q5VT06, Q66H17, Q69Z38, Q6A065, Q6AXY9, Q7SZL5, Q7TSH4, Q80TY4, Q80YD3, Q86UF4, Q86V48, Q8IWC1, Q8IWI9, Q8L7I1, Q8R4U7

Diamond homologs: A2AEY4, Q8IWC1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 122 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	70.1×	2e-10
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	61.9×	4e-10
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	61.9×	4e-10
Activation of BH3-only proteins	7	45.7×	4e-09
RHO GTPases activate PKNs	7	29.2×	1e-07
Loss of Nlp from mitotic centrosomes	13	27.1×	2e-13
Loss of proteins required for interphase microtubule organization from the centrosome	13	27.1×	2e-13
Intrinsic Pathway for Apoptosis	7	27.0×	2e-07

GO biological processes:

GO term	Partners	Fold	FDR
substantia nigra development	7	23.1×	4e-06
regulation of cytokinesis	6	22.8×	4e-05
centrosome cycle	6	18.2×	1e-04
protein targeting	5	16.5×	1e-03
intracellular protein localization	14	13.2×	2e-09
long-term synaptic potentiation	5	12.7×	2e-03
cilium assembly	11	7.3×	5e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

244 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	99
Likely benign	20
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

2365 predictions. Top by Δscore:

Variant	Effect	Δscore
X:136219391:GACTT:G	donor_loss	1.0000
X:136219392:ACTT:A	donor_loss	1.0000
X:136219393:CTTA:C	donor_loss	1.0000
X:136219394:TTAC:T	donor_loss	1.0000
X:136219395:TAC:T	donor_loss	1.0000
X:136219396:A:AC	donor_gain	1.0000
X:136219396:AC:A	donor_gain	1.0000
X:136219396:ACCC:A	donor_loss	1.0000
X:136219397:C:CC	donor_gain	1.0000
X:136219397:CC:C	donor_gain	1.0000
X:136220960:ATGG:A	acceptor_gain	1.0000
X:136220961:TGG:T	acceptor_gain	1.0000
X:136220964:C:CC	acceptor_gain	1.0000
X:136222388:CTAA:C	donor_loss	1.0000
X:136222390:AACC:A	donor_loss	1.0000
X:136222391:ACCTG:A	donor_loss	1.0000
X:136222482:GTGAC:G	acceptor_gain	1.0000
X:136222483:TGAC:T	acceptor_gain	1.0000
X:136222484:GAC:G	acceptor_gain	1.0000
X:136222485:AC:A	acceptor_gain	1.0000
X:136222486:CC:C	acceptor_gain	1.0000
X:136222487:C:CC	acceptor_gain	1.0000
X:136222490:CGAT:C	acceptor_gain	1.0000
X:136222493:T:C	acceptor_gain	1.0000
X:136222493:T:TC	acceptor_gain	1.0000
X:136226010:CTTT:C	acceptor_gain	1.0000
X:136227254:ATCC:A	donor_gain	1.0000
X:136227280:AAAC:A	donor_loss	1.0000
X:136227281:AACC:A	donor_loss	1.0000
X:136227282:ACC:A	donor_loss	1.0000

AlphaMissense

5790 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:136224878:T:A	R714S	0.997
X:136224878:T:G	R714S	0.997
X:136225915:C:A	R711S	0.997
X:136225915:C:G	R711S	0.997
X:136244681:C:G	R123P	0.996
X:136224867:A:C	I718S	0.995
X:136224867:A:G	I718T	0.995
X:136225925:C:G	R708P	0.995
X:136246094:C:G	R75P	0.995
X:136225912:T:A	K712N	0.994
X:136225912:T:G	K712N	0.994
X:136224863:C:A	M719I	0.991
X:136224863:C:G	M719I	0.991
X:136224863:C:T	M719I	0.991
X:136225913:T:A	K712I	0.991
X:136224858:C:G	R721P	0.990
X:136225916:C:A	R711M	0.990
X:136225916:C:G	R711T	0.990
X:136224879:C:G	R714T	0.987
X:136244702:C:G	R116P	0.986
X:136244670:C:G	A127P	0.984
X:136224880:T:C	R714G	0.982
X:136241265:C:G	A144P	0.982
X:136246333:C:G	A27P	0.982
X:136225970:C:G	R693P	0.981
X:136228690:G:T	R607S	0.981
X:136241240:C:G	R152P	0.981
X:136225914:T:C	K712E	0.980
X:136225940:T:G	Q703P	0.980
X:136244711:A:G	L113P	0.980

dbSNP variants (sampled 300 via entrez): RS1000053954 (X:136222648 C>T), RS1000086069 (X:136236799 T>A,C), RS1000157967 (X:136221616 C>T), RS1000224291 (X:136249801 G>A), RS1000276577 (X:136248171 G>A,T), RS1000414876 (X:136240123 C>T), RS1000507485 (X:136222102 C>T), RS1000518635 (X:136232874 C>A,T), RS1000831944 (X:136234045 G>C), RS1000879491 (X:136233715 T>A), RS1000999865 (X:136215325 G>A), RS1001110027 (X:136224680 A>G), RS1001252299 (X:136239733 A>C), RS1001304371 (X:136235065 G>A), RS1001426306 (X:136231243 G>A)

Disease associations

OMIM: gene MIM:300930 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Limited	X-linked

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724641 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.55	IC50	280	nM	MOLIBRESIB

PubChem BioAssay actives

1 with measured affinity, of 6 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178825: Inhibition of MAP7D3 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.2800	uM

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases reaction, decreases expression, increases abundance, affects binding	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
potassium chromate(VI)	decreases expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
abrine	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Acetaminophen	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cisplatin	affects cotreatment, decreases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Estradiol	increases expression	1
Lead	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Perfume	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	increases methylation	1
Sodium Selenite	increases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697555	Binding	Inhibition of MAP7D3 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice